Regulation of lymphokine-activated killer activity in T-replete and T-cell-depleted human bone marrow by interleukin 4. Exp Hematol 1991 Oct;19(9):950-7
Date
10/01/1991Pubmed ID
1716592Scopus ID
2-s2.0-0025816631 (requires institutional sign-in at Scopus site) 1 CitationAbstract
Donor-derived lymphokine-activated killer (LAK) cells appear to play a role in mediating an antileukemia effect in recipients of both T-replete and T-cell-depleted (TCD) bone marrow transplants. LAK activity, however, is subject to regulation by cytokines other than interleukin 2 (IL-2). The purpose of this study was to examine the effect of interleukin 4 (IL-4) on the induction of LAK activity in both T-replete and TCD bone marrow. IL-4 inhibited the induction of LAK activity in a time- and dose-dependent manner in both T-replete and TCD bone marrow cultures, although there appeared to be a differential effect, suggesting that T and non-T LAK precursors have different thresholds of sensitivity to IL-4. Single-cell cytotoxicity assays indicated that IL-4 did not inhibit binding of LAK effectors to targets but did reduce the frequency of lytic conjugates. Kinetic analysis techniques demonstrated that IL-4 decreased the maximal rate of target cell lysis by IL-2-activated LAK precursors and inhibited the rate of lytic programming. These data indicate that IL-4 is able to regulate the induction of LAK activity in both T-replete and TCD bone marrow and may play a role in modulating the generation of effector cells with potential antileukemia reactivity in vivo.
Author List
Drobyski WR, LeFever AV, Truitt RLAuthors
William R. Drobyski MD Professor in the Medicine department at Medical College of WisconsinRobert L. Truitt PhD Emeritus Professor in the Pediatrics department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Antigens, CDAntigens, Differentiation, T-Lymphocyte
Bone Marrow
Bone Marrow Cells
CD3 Complex
CD56 Antigen
Cell Adhesion
Cell Separation
Dose-Response Relationship, Drug
Down-Regulation
Humans
Interleukin-2
Interleukin-4
Killer Cells, Lymphokine-Activated
Lymphocyte Activation
Phenotype
Receptors, Antigen, T-Cell
Recombinant Proteins
T-Lymphocytes
